With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Hims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information ... The FDA recently ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.